Gut - Brain - Ovary Axis in Polycystic Ovary Syndrome: Microbiota, Metabolic Inflammation, and Reproductive Dysfunction
DOI:
https://doi.org/10.12775/JEHS.2026.89.69973Keywords
polycystic ovary syndrome, gut microbiota, gut-brain-ovary axis, insulin resistance, chronic inflammation, probioticsAbstract
Introduction
Polycystic ovary syndrome (PCOS) is a complex endocrine disorder characterized by reproductive, metabolic, and inflammatory disturbances. Increasing evidence suggests that gut microbiota plays a significant role in the regulation of metabolic and neuroendocrine pathways involved in PCOS.
Aim
The aim of this review was to summarize current knowledge on the gut-brain-ovary axis in PCOS, with particular focus on the contribution of gut microbiota dysbiosis to metabolic inflammation and reproductive dysfunction.
Material and methods
A narrative review of the literature was conducted using PubMed/MEDLINE, Scopus, and Web of Science databases. Peer-reviewed articles published in English up to March 2024 were analyzed. Studies addressing associations, underlying mechanisms, and therapeutic interventions linking gut microbiota with metabolic, inflammatory, neuroendocrine, and reproductive features of PCOS were included.
Results
Available evidence indicates that women with PCOS exhibit significant alterations in gut microbiota composition, including reduced microbial diversity, decreased abundance of short-chain fatty acid-producing bacteria, and increased prevalence of pro-inflammatory taxa. These changes are associated with insulin resistance, impaired intestinal barrier function, metabolic endotoxemia, chronic low-grade inflammation, hyperandrogenism, and disturbances in hypothalamic-pituitary-ovarian signaling.
Conclusions
Gut microbiota dysbiosis appears to play an important integrative role in the pathophysiology of PCOS by linking metabolic inflammation with neuroendocrine and ovarian dysfunction. The gut-brain-ovary axis represents a promising conceptual framework and therapeutic target; however, further well-designed longitudinal and mechanistic studies are required.
References
1. Teede HJ, Joham AE, Paul E, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Hum Reprod. 2023;38(9):1606-1612. doi:10.1093/humrep/dead123
2. Tay CT, Teede HJ, Joham AE, et al. Cardiovascular health in polycystic ovary syndrome: 2023 guideline update. J Am Heart Assoc. 2024;13:e033572. doi:10.1161/JAHA.124.033572
3. Chu W, Han Q, Xu J, et al. Metagenomic analysis identified microbiome alterations in polycystic ovary syndrome. Fertil Steril. 2020;113(6):1286-1298.e4. doi:10.1016/j.fertnstert.2020.02.012
4. González F. Inflammation in polycystic ovary syndrome: underpinning insulin resistance and ovarian dysfunction. Steroids. 2021;172:108857. doi:10.1016/j.steroids.2021.108857
5. Rizk MG, Thackray VG. Intersection of insulin resistance, inflammation, and gut microbiota in polycystic ovary syndrome. Reproduction. 2021;161(4):R91-R103. doi:10.1530/REP-20-0521
6. Torres PJ, Skarra DV, Ho BS, et al. Gut microbial diversity in women with polycystic ovary syndrome correlates with hyperandrogenism. J Clin Endocrinol Metab. 2021;106(2):e822-e834. doi:10.1210/clinem/dgaa778
7. Cani PD, Van Hul M. Gut microbiota and obesity: causally linked? Nat Rev Endocrinol. 2020;16(10):540-556. doi:10.1038/s41574-020-0405-y
8. Zeng B, Lai Z, Sun L, et al. Structural and functional profiles of gut microbiota in women with polycystic ovary syndrome with insulin resistance. Microbiome. 2020;8:124. doi:10.1186/s40168-020-00916-2
9. Guo Y, Qi Y, Yang X, et al. Association between polycystic ovary syndrome and gut microbiota. PLoS One. 2021;16(4):e0249262. doi:10.1371/journal.pone.0249262
10. Lindheim L, Bashir M, Münzker J, et al. Alterations in gut microbiome composition and barrier function in polycystic ovary syndrome. J Clin Endocrinol Metab. 2020;105(6):e2323-e2332. doi:10.1210/clinem/dgaa072
11. Zhao X, Jiang Y, Xi H, et al. Gut microbiota and inflammation in polycystic ovary syndrome. Front Cell Infect Microbiol. 2022;12:805979. doi:10.3389/fcimb.2022.805979
12. Sun Y, Li L, Chen Y, et al. Gut microbiota dysbiosis in polycystic ovary syndrome: mechanisms and therapeutic perspectives. Front Endocrinol (Lausanne). 2023;14:1189732. doi:10.3389/fendo.2023.1189732
13. Qi X, Yun C, Pang Y, Qiao J. The impact of the gut microbiota on the reproductive and metabolic endocrine system. Gut Microbes. 2021;13(1):1898790. doi:10.1080/19490976.2021.1898790
14. Schiller CE, Johnson SL, Abate AC, et al. The role of inflammation in reproductive endocrinology. Endocr Rev. 2022;43(1):1-34. doi:10.1210/endrev/bnab040
15. Huang F, Deng Y, Zhang M, et al. Fecal microbiota transplantation from patients with polycystic ovary syndrome induces metabolic disorders and ovarian dysfunction in germ-free mice. BMC Microbiol. 2024;24(1):364. doi:10.1186/s12866-024-03123-5
16. Mao RL, Zhang Y, Liu Y, et al. Causal relationships between gut microbiota and polycystic ovary syndrome: a Mendelian randomization study. Acta Obstet Gynecol Scand. 2024;103(4):403-412. doi:10.1111/aogs.14587
17. Li J, Zhao F, Wang Y. Gut microbiota and risk of polycystic ovary syndrome: a Mendelian randomization study. Heliyon. 2023;9:e16932. doi:10.1016/j.heliyon.2023.e16932
18. Karamali M, Eghbalpour S, Rajabi S, et al. Effects of probiotic supplementation on hormonal and inflammatory profiles in women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2021;94(2):275-283. doi:10.1111/cen.14382
19. Arab A, Karimi E, Vafa M. Probiotic supplementation in women with polycystic ovary syndrome: a randomized double-blind placebo-controlled trial. Clin Nutr ESPEN. 2022;49:220-227. doi:10.1016/j.clnesp.2022.02.030
20. Zhang Q, Hu N, Wang X, et al. Metformin improves metabolic abnormalities in polycystic ovary syndrome by modulating gut microbiota. Front Endocrinol (Lausanne). 2021;12:701313. doi:10.3389/fendo.2021.701313
21. He F, Li Y, Yu L, et al. Alterations of gut microbiota in women with polycystic ovary syndrome: a cross-sectional study. BMC Endocr Disord. 2020;20:182. doi:10.1186/s12902-020-00639-1
22. Zhang J, Sun Z, Jiang S, et al. Gut microbiota dysbiosis and insulin resistance in polycystic ovary syndrome. Front Endocrinol (Lausanne). 2020;11:620. doi:10.3389/fendo.2020.00620
23. Yoost JL, McNamara M, Smith K. Diagnostic value of bile acids and fibroblast growth factor-19 in polycystic ovary syndrome. Womens Health Rep. 2022;3:521-529. doi:10.1089/whr.2022.0027
24. Lingaiah S, Morin-Papunen L, Piltonen TT. Markers of intestinal permeability and dysbiosis in polycystic ovary syndrome. Endocr Connect. 2021;10(9):1136-1146. doi:10.1530/EC-21-0240
25. Salmeri N, Villari D, Cannarella R, et al. Gut microbiota and polycystic ovary syndrome: from pathophysiology to new therapeutic perspectives. Reprod Sci. 2022;29(6):1732-1746. doi:10.1007/s43032-021-00795-2
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Jakub Lech, Anna Marcinkowska, Julia Nowosielska, Karol Stobiński, Aleksandra Płusa, Natalia Pluta, Patryk Barczuk, Urszula Załuska, Weronika Kopyt, Katarzyna Latalska

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 4
Number of citations: 0